دانلود رایگان مقاله انگلیسی الگوریتم درمانی ضروری برای ازدیاد پلاکتهای خون ترمبوسیتمی - NCBI 2018

عنوان فارسی
الگوریتم درمانی ضروری برای ازدیاد پلاکتهای خون ترمبوسیتمی 2018
عنوان انگلیسی
Essential thrombocythemia treatment algorithm 2018
صفحات مقاله فارسی
0
صفحات مقاله انگلیسی
6
سال انتشار
2018
نشریه
Ncbi
فرمت مقاله انگلیسی
PDF
کد محصول
E8065
رشته های مرتبط با این مقاله
پزشکی
گرایش های مرتبط با این مقاله
خون و آنکولوژی، خون شناسی
مجله
مجله سرطان خون - Blood Cancer Journal
دانشگاه
Division of Hematology - Department of Medicine - Mayo Clinic - Rochester - USA
چکیده

Abstract


Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia (ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong survival. Fortunately, prognosis in ET and PV is relatively good, with median survivals in younger patients estimated at 33 and 24 years, respectively. Therefore, when it comes to treatment in ET or PV, less is more and one should avoid exposing patients to new drugs that have not been shown to be disease-modifying, and whose long-term consequences are suspect (e.g., ruxolitinib). Furthermore, the main indication for treatment in ET and PV is to prevent thrombosis and, in that regard, none of the newer drugs have been shown to be superior to the time-tested older drugs (e.g., hydroxyurea). We currently consider three major risk factors for thrombosis (history of thrombosis, JAK2/MPL mutations, and advanced age), in order to group ET patients into four risk categories: “very low risk” (absence of all three risk factors); “low risk” (presence of JAK2/MPL mutations); “intermediate-risk” (presence of advanced age); and “high-risk” (presence of thrombosis history or presence of both JAK2/MPL mutations and advanced age). Herein, we provide a point-of-care treatment algorithm that is risk-adapted and based on evidence and decades of experience.

نتیجه گیری

Conclusions


The most important first step in the management of ET is to confirm the accuracy of the diagnosis and make sure that other myeloid neoplasms, which might mimic ET in their presentation (e.g., prefibrotic PMF, masked polycythemia vera, chronic myeloid leukemia, refractory anemia with ring sideroblasts, and thrombocytosis), are excluded. Most patients with WHO-defined ET can expect a normal life expectancy with very low risk of leukemic transformation or fibrotic progression and a diagnosis of ET should not deter one from continuing with normal life activities, including sports, air travel, and pregnancy. Patients with ET should be informed about their driver mutational status and its prognostic and therapeutic implications. In this regard, aspirin therapy is very important for JAK2-mutated patients, because of their increased risk for arterial thrombosis. MPL mutations are infrequent in ET (~3%) and their presence raises the possibility of occult prefibrotic PMF or an increased risk of fibrotic progression. Observation alone remains a viable treatment option for “very low-risk” patients with ET while all other patients might benefit from aspirin therapy, in a once- or twice-daily schedule. In addition, cytoreductive treatment is strongly encouraged in patients with thrombosis history, and our first- and second-line drugs of choice in this regard are hydroxyurea and pegylated IFN-α, respectively. On the other hand, we no longer insist on the use of cytoreductive therapy in older patients without previous vascular events, provided they are JAK2/MPL unmutated.


بدون دیدگاه